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ABSTRACT
Background In the curative- intent treatment of locally 
advanced lung cancer, significant morbidity and mortality 
can result from thoracic radiation therapy. Symptomatic 
radiation pneumonitis occurs in one in three patients and 
can lead to radiation- induced fibrosis. Local failure occurs 
in one in three patients due to the lungs being a dose- 
limiting organ, conventionally restricting tumour doses 
to around 60 Gy. Functional lung imaging using positron 
emission tomography (PET)/CT provides a geographic map 
of regional lung function and preclinical studies suggest 
this enables personalised lung radiotherapy. This map of 
lung function can be integrated into Volumetric Modulated 
Arc Therapy (VMAT) radiotherapy planning systems, 
enabling conformal avoidance of highly functioning regions 
of lung, thereby facilitating increased doses to tumour 
while reducing normal tissue doses.
Methods and analysis This prospective interventional 
study will investigate the use of ventilation and perfusion 
PET/CT to identify highly functioning lung volumes and 
avoidance of these using VMAT planning. This single- arm 
trial will be conducted across two large public teaching 
hospitals in Australia. Twenty patients with stage III 
non- small cell lung cancer will be recruited. All patients 
enrolled will receive dose- escalated (69 Gy) functional 
avoidance radiation therapy. The primary endpoint is 
feasibility with this achieved if ≥15 out of 20 patients meet 
pre- defined feasibility criteria. Patients will be followed for 
12 months post- treatment with serial imaging, biomarkers, 
toxicity assessment and quality of life assessment.
Discussion Using advanced techniques such as VMAT 
functionally adapted radiation therapy may enable safe 
moderate dose escalation with an aim of improving local 
control and concurrently decreasing treatment related 
toxicity. If this technique is proven feasible, it will inform 
the design of a prospective randomised trial to assess 
the clinical benefits of functional lung avoidance radiation 
therapy.
Ethics and dissemination This study was approved by 
the Peter MacCallum Human Research Ethics Committee. 
All participants will provide written informed consent. 
Results will be disseminated via publications.
Trials registration number NCT03569072; Pre-results
INTRODUCTION
In the curative treatment of locally advanced 
non- small cell lung cancer (NSCLC), signif-
icant treatment- related morbidity and even 
mortality can result from thoracic radia-
tion therapy. The predominant mecha-
nism behind treatment- related toxicity is 
radiation effects on the lung manifesting as 
Strengths and limitations of this study
 ► This is a novel trial interventional trial integrat-
ing Galligas/68Ga- macroaggregated albumin 
respiratory- gated (4- dimensional) ventilation/perfu-
sion (positron emission tomography/CT) functional 
lung imaging into radiation treatment planning.
 ► Volumetric modulated arc therapy (VMAT) planning 
used in this trial aims to allow for moderate dose 
escalation to the primary only, while respecting con-
ventional normal tissue toxicity constraints.
 ► This single- arm study will assess the technical fea-
sibility of delivering personalised VMAT radiation.
 ► Radiation plans will be personalised to an individu-
al’s tumour location and spatial lung function.
 ► This single arm feasibility study is unable to assess 
effectiveness of reduction in pulmonary toxicity or 
enhanced tumour control but will nonetheless pro-
vide valuable information about the feasibility of 
conducting a larger- scale randomised trial.
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symptomatic radiation pneumonitis which occurs in up to 
one in three patients with fatal pneumonitis occurring in 
2% of patients.1 The risk of pneumonitis is related to the 
dose and volume of lung irradiated. Current lung dose 
volume constraints simplistically assume that the lungs are 
anatomically and functionally homogeneous. A number 
of factors increase pneumonitis risk further including the 
use of concurrent chemotherapy, interstitial lung disease 
and age.1 The need to limit lung dose and other organs 
for safety reasons may contribute to the high local failure 
rate in stage III disease in one in three patients.2–5
Integration of functional lung imaging into treatment planning
Lung imaging using inhaled Galligas and intravenously 
administered 68Ga- macroaggregated albumin (MAA) 
enables acquisition of four- dimensional (4D) ventilation 
and perfusion (V/Q) positron emission tomography 
(V/Q, positron emission tomography (PET)/CT).6 7 
This provides a 3D map of lung V/Q.8 Previous work has 
demonstrated a relationship between radiation therapy 
dose and change in V/Q as visualised V/Q PET/CT.9 10 
We have shown strong correlations between V/Q PET/
CT functional volumes and pulmonary function test 
parameters.11
Planning studies conducted on participants in the 
observational GalliPET clinical trial have shown feasibility 
of radiation therapy treatment planning personalised to 
an individual’s lung functional distribution; it has been 
demonstrated that integrating V/Q PET/CT information 
in radiation therapy planning can significantly reduce 
dose to functional lung.12 13 Systematic review of the liter-
ature has demonstrated reductions in functional lung 
dose can be achieved with the mean functional volume 
receiving 20 Gy reduced by: 4.42% (95% CI 1.66% to 
7.18%) for perfusion, 4.41% (95% CI 2.37% to 6.45%) for 
ventilation and 4.19% (95% CI 2.34% to 6.04%) overall 
when plans were optimised based on functional lung 
imaging.14 The mean functional lung dose was reduced 
by: 1.98 Gy (0.57: 3.39) for perfusion, 2.63 Gy (0.14: 5.12) 
for ventilation and 2.18 Gy (1.09: 3.26) overall when plans 
were optimised using functional lung imaging.14
Advances in radiation therapy planning
This functional map of lung can be integrated into volu-
metric modulated arc therapy (VMAT) advanced radiation 
therapy planning which can optimise radiation planning 
to avoid functional regions of lung. A number of studies 
have demonstrated improved dosimetry compared with 
other radiation therapy techniques for NSCLC.15 VMAT 
may enable safe dose escalation above the standard dose 
of 60 Gy with accurate normal tissue definition, motion 
management and functional avoidance. Another advance 
to VMAT planning is the introduction of more advanced 
techniques such as the use of non- coplanar arcs. This 
has been shown to significantly decrease heart dose by 
20%–30% in patients with lower lobe tumours treated 
with 74 Gy in 37 fractions.16
Radiobiological basis for dose escalation
74 Gy in 37 fractions at 2 Gy per fraction has been estab-
lished as the maximum tolerated safe dose in multiple 
phase 1/2 dose escalation studies.17 This was used as the 
basis for the phase 3 trial, RTOG 0617.2 This demon-
strated inferior local control and worse survival in the 
dose escalation arm.2 18 Further analysis of the RTOG 
0617 trial suggests that worse outcomes may relate to 
increased dose to organs at risk, especially the heart 
which may be able to be reduced with advanced plan-
ning techniques and a smaller volume being irradi-
ated at a higher dose using a simultaneous- integrated 
boost technique.5 18 With the current standard of care 
dose of 60 Gy mediastinal nodal failure is rare.19 There-
fore, there is renewed interest in escalating dose to the 
primary tumour which is a common site of failure while 
treating the nodal volumes to a standard dose of 60 Gy.20 
As mediastinal nodes are centrally located, maintaining 
a standard dose to these regions has the added benefit 
of not increasing dose to the central organs at risk 
such as the heart, oesophagus and proximal bronchial 
tree. Further analysis of dose escalation trials suggest 
there may be an overall survival benefit to a dose esca-
lated approach if it can be delivered without treatment 
prolongation.21 This form of dose escalation has not 
been tested with a consistent manner using advanced 
radiation therapy planning techniques.
METHODS AND ANALYSIS
This is a prospective single- arm interventional clinical trial 
assessing the technical feasibility of functionally adapted 
lung radiation therapy using V/Q PET/CT imaging and 
VMAT planning. The primary intervention is VMAT radi-
ation therapy optimised to avoid regions of functional 
lung delivered to a total dose of 60 Gy in 30 fractions to 
the primary and nodal planning target volume. A simul-
taneous integrated boost will be delivered to the primary 
tumour to a total dose of 69 Gy in 30 fractions. The trial 
schema is demonstrated in figure 1. The trial plans to 
recruit a total of 20 patients over two tertiary teaching 
hospitals in Melbourne, Australia.
Inclusion criteria
 ► Age ≥18 years.
 ► Informed consent documented and consent form 
signed.
 ► Histologically or cytologically confirmed NSCLC.
 ► ECOG performance status 0–2 within 2 weeks prior to 
registration.
 ► Locally advanced disease (stage IIIA, IIIB, IIIC AJCC, 
eighth ed.) as confirmed on staging 18F- fluorodeoxy-
glucose (FDG)- PET/CT with no evidence of metastatic 
intracranial disease on CT brain with contrast or MRI.
 ► Planned for treatment with curative intent.
Exclusion criteria
 ► Participant is not able to tolerate supine position for 
imaging.
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 ► If history of a prior extrathoracic invasive malignancy 
(except non- melanomatous skin cancer) must be free 
from recurrence for a minimum of 3 years at the time 
of registration.
 ► Prior radiation therapy to the lungs or mediastinum.
 ► Prior known history of interstitial lung disease.
Trial objectives
The primary objective of this study is to assess the tech-
nical feasibility of the delivery of personalised functional 
lung radiation therapy using V/Q PET/CT. This study 
will be considered feasible if all criteria defined below are 
achieved for ≥15 out of 20 patients.
Feasibility will be considered to have been achieved 
for a given patient if all of the following criteria are me 
when functional plans are compared with conventional 
anatomical plans: (A) Reduction in mean functional lung 
dose of ≥2 Gy and functional lung volume receiving 20 Gy 
of ≥4%; (B) Mean heart dose is ≤30 Gy and relative heart 
volume receiving 50 Gy is <25%.
The secondary objectives are:
1. To determine the incidence of grade ≥2 clinical or 
radiological pneumonitis after high dose functionally 
adapted radiation therapy.
2. To determine the incidence of grade ≥2 acute and late 
toxicities.
3. To quantify regional ventilation loss and regional per-
fusion loss on post treatment V/Q PET/CT following 
functionally adapted lung radiation therapy and its re-
lationship to spirometry and exercise tolerance.
4. To assess the relationships of cytokine release in pa-
tient’s plasma with grade ≥2 radiation pneumonitis.
5. To assess the associations between:
a. Ventilation PET/CT with inhale/exhale CT venti-
lation.
b. Perfusion PET/CT with dual energy CT iodine 
mapping (a surrogate for pulmonary perfusion).
6. To assess patient reported quality of life outcomes us-
ing the FACT- L quality of life questionnaire.
7. To assess incidence of complete metabolic response 
3- month post- treatment FDG- PET/CT.
8. To assess progression- free survival at 12 months follow-
ing completion of trial radiation therapy (defined by 
RECIST V.1.1).
9. To assess overall survival at 12 months following com-
pletion of trial radiation therapy.
The exploratory objectives are:
1. To assess the feasibility of conducting a radiation in-
duced lymphocyte apoptosis assay.
2. To investigate the utility of mid- treatment cardiac bio-
marker testing and pretreatment coronary calcium 
scoring to predict patients at greater risk of radiation 
induced cardiac toxicity.
3. To correlate primary and nodal disease metabolic pa-
rameters seen on pretreatment and post- treatment 
FDG- PET/CT with dual energy CT iodine quantifica-
tion.
4. To assess circulating tumour- DNA levels as a predictor 
of treatment response.
V/Q PET/CT procedure
The radiopharmaceuticals used in this study will be 
synthesised onsite by a qualified radio pharmacist using 
methods we have previously validated by our group.7 10 
68Ga will be eluted from our 68Ge/68Ga generator and 
used to label the appropriate precursor. 68Ga- Galligas 
is prepared using a Technegas generator except that 
the radionuclide technetium- 99m is replaced with 
gallium-68 in the carbon crucible inserted into the Tech-
negas synthesis unit. 68Ga- MAA is prepared as follows: A 
commercially available kit of MAA is washed three times 
with sterile milli- Q water dispensed into 1 mL aliquots 
with each aliquot containing MAA particles of between 
250 and 700 thousand particles. Gallium-68 obtained 
Figure 1 Demonstrates the trial schema from screening to the final assessment at 12 months post- treatment. AEs, adverse 
events; FDG, fluorodeoxyglucose; PET, positron emission tomography; RT, radiation therapy; VMAT, Volumetric Modulated Arc 
Therapy; V/Q, ventilation and perfusion.
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from the generator is buffered with acetate buffer to pH 
6–7 before adding to the MAA aliquot. The suspension 
mixture is allowed to incubate for 1 min at 90°C after the 
addition of radioactivity for the radiolabeling process. 
Quality control tests was performed in accordance with 
the British Pharmacopoeia for radiolabelled MAA before 
the compound is released for clinical use.
The methodology of the V/Q PET/CT will be as follows:
1. A peripheral intravenous catheter is installed in the 
arm.
2. Participant inhales approximately 5 MBq of 68Ga- 
Galligas, in semi- supine position, using the same tech-
nique as for Technegas.
3. A chest 4D- CT acquisition is performed (140 kVp, 30–
40 mA, axial scan time is breathing period +1 s.
4. Lung ventilation 3D list- mode respiratory gated PET 
acquisition is started (2–3 bed positions, 5 min per bed 
position). This acquisition will be reconstructed as 
both a respiratory gated and ungated scan.
5. Without moving, approximately 20–40 MBq 68Ga- MAA 
is injected intravenously, as a bolus, via the catheter. 
The syringe is then flushed with normal saline.
6. The lung perfusion 3D list- mode respiratory gated 
PET acquisition is started (2–3 bed positions, 5 min per 
bed position, exactly the same bed positions as for the 
ventilation study). This acquisition will be reconstruct-
ed as both a gated and ungated scan.
Personalised functional adapted VMAT radiation therapy
Technical description
Treatment planning will be done using the Varian Medical 
Systems, Palo Alto, California, Eclipse V.15.5 comput-
erised radiation therapy planning system. At least two 
VMAT arcs will be used to deliver the radiation therapy. 
The 360° arcs are to be avoided to minimise dose to the 
contralateral lung. It is expected individual arc length will 
typically be between 180° and 240°.
Radiation therapy volumes
Target volumes will be defined as per standard practice 
including the primary tumour and nodal gross tumour 
volumes (GTV), internal target volumes (ITV) and plan-
ning target volumes (PTV). GTV incorporating respira-
tory motion on 4D CT, the internal gross tumour volume 
(IGTV) will be contoured for the primary tumour. ITV 
as defined by ICRU70 will be used to take into account 
tumour movement through respiration and a margin 
for subclinical spread.22 Target delineation and margins 
applied to primary tumour and nodal volumes are as per 
institutional protocol including mandatory use of 4D CT, 
FDG- PET/CT fusion and diagnostic contrast enhanced 
CT.
Boost volume definition: The proximal bronchial tree will 
have an isotropic 3 mm PRV expansion named proximal 
bronchial tree PRV. The boost volume (IGTV_6900) will be 
given to the IGTV of the primary tumour alone minus the 
proximal bronchial tree PRV. Normal tissue contouring will 
follow the RTOG 1106 contouring atlas.23
Functional lung volumes
Nuclear medicine physicians in conjunction with the 
radiation oncologists will define visually adapted func-
tional lung subvolumes. The definitions and description 
of each functional lung grouping are described below. 
A 30% threshold was determined to separate regions of 
lung with higher potential function. On meta- analysis, 
this threshold was the most common threshold used 
when determining functional lung sub- volumes and 
similar to previously published thresholds using VQ 
PET.14 24
Name (full)
Short 
name Description
Perfused Q Lung Any Lung parenchyma containing 68Ga- MAA 
contoured using a visually adapted threshold 
that is confirmed by a physician.
Well 
Perfused
WQ 
Lung
Contour defined as 68Ga- MAA uptake greater 
than 30% of max.
Ventilated Vent 
Lung
Any Lung parenchyma containing Galligas 
contoured using a visually adapted threshold 
that is confirmed by a physician. If there was 
significant clumping of the Galligas in the central 
airways was observed this was excluding activity 
four SD above the mean25
Well 
Ventilated
WVent 
Lung
Contour defined as Galligas uptake greater than 
30% of max.
Galligas, 68Ga- carbon ultrafine aerosols; MAA, macroaggregates of human 
albumin.
These volumes are imported as DICOM structures into 
Eclipse. After visual verification, the radiation oncologist 
then uses these to generate the following opimisation struc-
tures. A graphical description of the components of all 
functional lung volumes is provided in figure 2.
Optimisation 
prioritisation Name (full) Name Description
1 High 
functioning
Lung HF Intersection of WVent lung and 
WQ lung, excluding PTV
2 Functioning Lung F Intersection of vent and Q 
contours excluding lung HF 
excluding PTV
3 Perfused Lung P Any lung parenchyma containing 
68Ga- macroaggregated albumin 
contoured using a visually 
adapted threshold that is 
confirmed by a physician. 
Excluding lung HF, lung F, 
excluding PTV
4 Ventilated Lung V Any lung parenchyma containing 
Galligas contoured using a 
visually adapted threshold that 
is confirmed by a physician. 
Excluding lung HF, lung F, lung P, 
excluding PTV
The expected outcome of these optimisation objec-
tives is demonstrated in figure 3 where axial and coronal 
slices demonstrate the 20 Gy isodose line. In the function-
ally adapted plan there is less of the 20 Gy isodose line 
overlapping with high functioning and functioning lung 
segments.
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Treatment planning
The investigational treatment will be prescribed ensuring 
that 98% of the 60 Gy PTV is covered by 98% of the 
dose. The 69 Gy in 30 fractions (9 Gy) boost sub- volume 
(IGTV_6900) will aim to achieve 95% of the IGTV receives 
100% of the boost dose (D95=100%). The maximum dose 
to PTV (PTV max) must be contained within the IGTV. 
This boost dose will be reduced if organ at risk planning 
constraints cannot be met. This will be at the discretion 
of the treating clinician. Dose constraints to organs at risk 
are described in table 1. If dose reduction is necessary, this 
event should be recorded and the D95% reported. Non- 
coplanar arcs may be considered if technically feasible 
and if this improves normal tissue sparing. It is expected 
that majority of patients will receive concurrent cytotoxic 
chemotherapy; the treating medical oncologist will deter-
mine the agents. Acceptable chemotherapy regimens 
include weekly carboplatin and paclitaxel and 3 weekly 
cisplatin and etoposide in accordance with Australian 
guidelines.26 27 Appropriate patients will also be offered 
adjuvant immunotherapy.28 This is not mandated by this 
study protocol.
Treatment delivery
All patients will have a pretreatment dosimetric quality 
assurance according to departmental VMAT quality assur-
ance guidelines. Daily Cone Beam CT (CBCT) will be 
performed with online soft tissue matching will ensure 
that the target is within the PTV.
Statistical considerations
The study sample size is pragmatic and based on the clin-
ically relevant number of patients needed to determine 
the technical feasibility of the functional lung sparing 
VMAT radiation therapy technique. Table 2 demonstrates 
the 95% CIs for different scenarios of feasibility rates.
The study follow- up duration was designed to be prag-
matic for a feasibility study while having enough follow- up 
Figure 2 Demonstrates a spatial description of each of the lung subvolumes created by integrating functional information from 
the V/Q PET/CT is used to create optimisation functional lung subvolumes which are used in VMAT radiation therapy planning. 
PET, positron emission tomography; VMAT, Volumetric Modulated Arc Therapy; V/Q, ventilation and perfusion.
Figure 3 The arrows demonstrate the 20 Gy isodose line in radiation therapy plans optimised with conventional (anatomically 
based) lung constraints (left) and integrating functional information from V/Q PET/CT (right). PET, positron emission tomography; 
V/Q, ventilation and perfusion.
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duration to detect clinically significant toxicity. In the 
context of NSCLC radiation therapy, late cardiac and 
lung toxicity typically presents within a 12- month time 
period. Our recent systematic review showed that func-
tional lung imaging dose–response relationships plateau 
around 6–12 months post- treatment.14 29
Main analysis of the primary endpoint will be performed 
after all patients have been registered and completed 
their 3- month follow- up assessment. A final analysis will 
be performed at the completion of the study, which will 
be 12 months after the final patient completes treatment.
Monitoring programmes
Prior to commencement of radiation therapy, contours 
undergo peer review and sign off by a qualified radiation 
oncologist. All radiation therapy plans undergo review by 
a senior radiation therapist and senior medical physicist. 
Pretreatment dosimetric quality assurance is required 
prior to delivery of the first fraction.
All trial personnel are required to be qualified for 
their designated role with suitable training provided and 
credentials certified by the principal investigator. On 
treatment, weekly clinical reviews are performed a creden-
tialed physician. At these assessments, offline CBCT 
assessment is performed to ensure adequate coverage of 
target volumes and review organs at risk. Post- treatment 
assessments must also be performed by a credentialed 
physician.
Independent trial monitoring
An independent data monitoring committee will be 
appointed and will convene with the purpose of:
 ► Assessing quality issues related to radiation therapy.
 ► Assessing the conduct and progress of the trial—
accrual, non- eligibility, treatment toxicity and serious 
adverse events.
SAEs will be forwarded to the data monitoring 
committee. If three SAEs are recorded during the trial, 
Table 1 This table demonstrates the normal tissue constraints used in the radiation therapy planning process
Structure Metric Per protocol Source
Bony spinal canal Max dose 0.03cc ≤50 Gy 13
Oesophagus Max dose 0.03cc <63 Gy 13
Mean <34 Gy 13
Heart V40 <30%   
V50 <25% 33
Mean <20 Gy 5
Max dose 0.03cc <70 Gy 13
Brachial plexus Max dose 0.03cc <63 Gy 13
Proximal bronchial tree Max dose 1.0cc <64.5 Gy 3
Great vessels (normal) Max dose 0.03cc <80 Gy 34
Great vessels (tumour involved) Max dose 0.03cc <70 Gy 34
Lung dose constraints
Structure Metric Per protocol Definition Source
Lungs (anatomic) Mean <20 Gy Mean dose to the whole anatomic lung 13
Left+right lung- IGTV V30 <30% Volume of structure (%) receiving ≥30 Gy 13 35
V20 <35% Volume of structure (%) receiving ≥20 Gy 13 35
V5 <66% Volume of structure receiving ≥5 Gy 13 35
Table 2 This demonstrates shows the exact 95% CIs for different scenarios of feasibility rates
No of feasible cases Feasibility rate, %
Exact 95% CIs for rate estimate
Lower limit, % Upper limit, %
15 75 51 91
16 80 56 94
17 85 62 97
18 90 68 99
19 95 75 100
20 100 83 100
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the data monitoring committee must convene and deter-
mine the causal link between SAEs and the research. An 
assessment must be made regarding early termination of 
the trial, and recommendations forwarded to the Peter 
MacCallum Ethics Committee. The data monitoring 
committee should also convene at the completion of the 
trial to assess safety of this project.
Data collection and record retention
All data will be stored in reidentifiable form on Research 
Electronic Data Capture in a password- protected 
computer database.30 Any paper data will be stored in 
a locked filing cabinet in a secure building. Data will 
be stored for a minimum of 7 years after publication of 
study results, in accordance with Institutional guidelines 
and the Australian Code for the Responsible Conduct of 
Research. Patient confidentiality will be maintained at all 
times.
Ethics and dissemination
This study was approved by the Peter MacCallum Human 
Research Ethics Committee (HREC/18/PMCC/23). 
Prior studies have demonstrated safety of V/Q PET/CT.10 
The stochastic and deterministic risks of radiation doses 
used in trial investigations and treatment have been care-
fully assessed and detailed in the trial participant informa-
tion and consent form. The study results will be published 
in peer- reviewed journals.
DISCUSSION
Advanced techniques such as VMAT functionally adapted 
radiation therapy may enable safe moderate dose esca-
lation without treatment prolongation with an aim of 
improving local control and concurrently decreasing 
treatment related toxicity. The long- term results from 
the RTOG 0617 trial demonstrated worse survival in 
the dose- escalation arm. Long- term follow- up suggests 
this mechanism is primarily through radiation injury 
to the central structures of the heart and oesophagus.18 
Advanced imaging and VMAT planning allow these struc-
tures to be precisely defined and using strict normal tissue 
constraints moderate dose escalation to the primary 
tumour alone may enable safe dose escalation without 
treatment prolongation.
The paradigm for the management of stage III lung 
cancer has changed significantly with the introduction 
of consolidation immunotherapy. Patients who receive 
consolidation durvalumab in the PACIFIC trial demon-
strated an improvement in 3- year overall survival to 
57.0% compared with 43.5% in the group randomised to 
placebo.28 Although this treatment has improved survival 
in this patient cohort, additional toxicities involved with 
immunotherapy have been documented with pneu-
monitis occurring more frequently in patients treated 
with immunotherapy.31 Prior radiation to the lungs is a 
known risk factor for this toxicity.32 Advanced functional 
imaging with V/Q PET/CT and planning to avoid highly 
functional regions of lung may minimise this risk of 
toxicity.
Currently, little is understood about why certain patients 
experience radiation induced toxicity. The pretreatment, 
mid- treatment and post- treatment imaging and blood 
biomarkers being investigated in this trial in an explor-
atory manner may provide useful hypotheses to enable 
further research into better understanding treatment 
related toxicity. If feasible, this technique will allow a 
prospective randomised trial to assess the clinical benefits 
of functional lung avoidance radiation therapy.
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